No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Sonde Health Launches New Voice-Enabled Health Screening Tool to Help Employers Return to Work During the Global Pandemic

Editor: What To Know

  • As businesses across the country grapple with how to safely bring employees back to the physical workplace, a new voice-enabled health detection and monitoring app from Sonde Health promises to potentially help employers improve employee safety, meet government mandates, and satisfy their own administrative needs as they reopen office doors in a rapidly changing COVID-19 environment.
  • “From the conference room to the warehouse floor, the Sonde One app will help us standardize our return to work policy to eliminate any confusion and keep all employees feeling safe.
  • Sonde One is an easy, non-invasive way for organizations to manage employee health risks during the pandemic and potentially get workers back to the office safely.

Sonde Health: As businesses across the country grapple with how to safely bring employees back to the physical workplace, a new voice-enabled health detection and monitoring app from Sonde Health promises to potentially help employers improve employee safety, meet government mandates, and satisfy their own administrative needs as they reopen office doors in a rapidly changing COVID-19 environment.

Sonde Health calls the new tool, called Sonde One, leverages the company’s advanced vocal biomarker platform and machine learning technology. With a single 6-second voice sample, the app is designed to quickly and objectively detect respiratory symptoms, such as coughing, shortness of breath, or chest tightness or pain. The app combines this voice analysis with a comprehensive, CDC-informed COVID-19 questionnaire and user-inputted body temperature to give employees clear instructions about where they can work within one minute. Employers can deploy the solution to any number of staff anywhere and make daily informed decisions regarding who can go into the workplace or who should work from home, without requiring new equipment or workflows.

“At Sonde, we believe that voice is a vital sign and a meaningful predictor of health,” said David Liu, Chief Executive Officer for Sonde Health. “By analyzing a few seconds of speech, we can detect subtle changes in a person’s voice caused by common symptoms of respiratory disease. We built this capability into the Sonde One app so organizations can provide their employees with simple and fast COVID-19 monitoring in their pocket.”

To bring Sonde One to market, Sonde has partnered with corporate wellness solutions provider Wellworks for You to make the tool available to its clients and their 1.4 million participating members. SHI International, a 5,000-person global provider of technology products and services, is the first enterprise to enroll. The company will begin implementing the Sonde One app in August, as it gradually begins bringing employees back to the workplace, starting with its Somerset, NJ headquarters.

“After months of remote work and distributed workforces, many employers want to get their employees back in the office; they’re just not sure of the best way to do it,” says Thomas Tegler, President of Wellworks for You. “At Wellworks for You, we’re always seeking better ways to promote employee wellness and preventative care, and in today’s healthcare climate, Sonde Health provides a novel solution. Sonde One is an easy, non-invasive way for organizations to manage employee health risks during the pandemic and potentially get workers back to the office safely.”

“As we navigate this pandemic, our employees’ health and wellness is our top priority,” says Michael Haluska, Vice President of Human Resources for SHI International. “From the conference room to the warehouse floor, the Sonde One app will help us standardize our return to work policy to eliminate any confusion and keep all employees feeling safe.”

Sonde One can be customized to each employer’s return to work policy, giving employees clear guidance on whether they should or should not report for physical duty following each screening. Additionally, a QR code can be delivered to employees within the app and scanned at an organization’s front door to confirm compliance with protocols. Secure and customizable reporting capabilities enable employers to confirm employee participation, satisfy enterprise needs, and adhere to mandatory state guidelines surrounding employee screening and documentation.

Once an employer signs on, employees can download their employer-specific app via the App Store or Google Play on any smartphone, allowing for fast, simple deployment across enterprises.

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy